Jeanmarie Guenot is currently the president of one of the biggest firm, Amphivena Therapeutics Inc, dedicated to manufacturing immune therapies to help in treating cancer. She has had the opportunity of serving the medical industry in both public and private sector for more than twenty years. She is the founder of Guenot LLC; a company specialized in offering consultation services such as licensing, economic planning, project management, mergers and acquisitions, alliance management services to both pharmaceuticals and biotechnology organizations. JeanMarie is also involved in pharmaceutical products and venture capital, project management and commercial development.
Prior to becoming the Amphivena president, Jeanmarie had an opportunity of gaining her experience from working in different firms in various roles. She once served as a business consultant for one year for Hoffmann. She worked at PDL BioPharma as a VP of Business and Corporate Development that assisted in shaping her leadership skills. As the VP, she oversaw the licensing, acquisitions and managed R&D commercial portfolios. To acknowledge all her efforts, she was awarded the BioBusiness Network Innovative Bio-Partnering Award which was in 2005 for being able to make a 50-50 deal between PDL and Hoffmann-La Roche.
LinkedIn portrays JeanMarie as an individual who is fully trained in designing drugs, semi-empirical methods, refinement, medicinal and physical chemistry and so on. Her education has played a bigger role in her career journey as she studied at the University of California where she earned her Ph.D. and MBA from the University of Pennsylvania. In specific, her scientific career started at Hoffmann while her business career began at Atlas Ventures. At Hoffmann, she was the principal scientist where she helped in developing drugs for inflammation, oncology, autoimmune and metabolic diseases. At Atlas Ventures, she majorly managed the ventures capital investments.
Jeanmarie Guenot continues working hard knowing that with what she is doing, a life is saved somewhere and a cancer patient gets a second chance at life.